ClinConnect ClinConnect Logo
Search / Trial NCT06087861

5-Day Preoperative Radiation for Soft Tissue Sarcoma

Launched by STANFORD UNIVERSITY · Oct 11, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating a new approach to treating soft tissue sarcoma, which is a type of cancer that can occur in various parts of the body, including the arms, legs, and trunk. The study looks at giving patients a shorter course of radiation therapy before surgery—just five days instead of the usual 25 days. The goal is to determine if this shorter treatment is safe and effective in helping patients prepare for their surgery.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of soft tissue sarcoma. They should also be eligible for standard preoperative radiation and surgery, and have a reasonable life expectancy. Participants will receive the radiation treatment over five days, followed by surgery. It’s important for potential participants to understand that those who have had prior radiation in the treatment area, are currently using other anti-cancer medications, or are pregnant cannot join the study. This trial is currently recruiting, and it offers a chance to help improve future cancer treatments while also receiving care for their condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Histologically confirmed soft tissue sarcoma of the extremity, trunk or retroperitoneum.
  • 2. Has been offered preoperative radiation and surgery as part of standard-of-care treatment
  • 3. Age ≥ 18
  • 4. KPS ≥ 70 or ECOG 0 to 2
  • 5. Life expectancy ≥ 6 months
  • 6. If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented.
  • 7. Ability to understand and the willingness to personally sign the written IRB approved informed consent document.
  • Exclusion Criteria:
  • 1. History of prior radiation to the area to be treated.
  • 2. Active use of other anti-cancer investigational agents.
  • 3. Planned use of concurrent chemotherapy, targeted therapy, or immunotherapy with radiation therapy (defined as the time interval starting 1 week before the first and last fraction of radiation therapy and surgery).
  • 4. Pregnancy.

About Stanford University

Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.

Locations

Palo Alto, California, United States

Patients applied

0 patients applied

Trial Officials

Anusha Kalbasi, MD

Principal Investigator

Stanford University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported